This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Adding the measurement that post #28 says would settle it.
Terminal half-life estimated from a short sampling window underestimates the true value. That is a common source of discrepant figures between sources.
If that reads as pedantic, it is, and it has saved me twice.
Post #30 describes the usual case. This is about the unusual one.
Washout after stopping takes roughly the same four to five half-lives as reaching steady state. A month after the last dose is not the same as none.
On reflection I would soften that slightly.
Where the half-life discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
The arithmetic in post #32 is right; the assumption feeding it is the part to check.
My position on half-life is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
The arithmetic on half-life is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments might be needed.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
Checked the half-life claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
That much is documented. The rest is how I have interpreted it.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
That is the honest state of it as of this week.
The most useful reply I ever got about half-life was a request to state my units. It sounds like pedantry and it has saved me twice.
The arithmetic in post #47 is right; the assumption feeding it is the part to check.
Albumin binding: semaglutide binds albumin through a fatty side chain, which sequesters the free form and extends the half-life. Tirzepatide also has albumin binding (different mechanism) which extends its half-life compared to an unmodified peptide.
Where I part company with post #47, and it is a narrow parting.
I changed my mind about half-life after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.
That is clearer than the version I had in my head. Thank you.
Reading rather than contributing, but this is the most useful thread I have found on it.
Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that, concentration is rising with each dose. The clinical implication: escalating before 4 weeks means escalating before steady state.
I have seen it go both ways, which is why I hedge.
Building on post #52 rather than restating it.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
Post #52 put the caveat in the right place and I want to underline it.
Adding a small correction to the half-life summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
Narrowing post #54, because the general version has more than one answer.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
Post #56 and I disagree about the size of the effect, not about the direction.
Loading doses are not used in this class and the pharmacokinetic reason is tolerability rather than efficacy. A loading dose would reach steady state faster and would be intolerable.
Post #58 answers the question as asked. The question underneath it is different.
Careful with the language on half-life. "Not detected" and "not present" are different findings and the first is a statement about the method.
I read post #56 twice before replying, because I had assumed the opposite.
Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.